Abstract: A flow control device for a compressible bottle may include a reservoir, the reservoir comprising an ophthalmic formulation disposed therein, the ophthalmic formulation comprising an ophthalmic agent and a preservative; a reservoir interface, disposed at a mouth of the reservoir, the reservoir interface comprising one or more apertures, the one or more apertures in the reservoir interface fluidically connecting an interior of the reservoir and an exterior of the reservoir; a nozzle, the nozzle comprising: an outlet and a nozzle cap, the nozzle cap comprising one or more apertures, the one or more apertures in the nozzle cap fluidically connecting the outlet and a reservoir-facing surface of the nozzle; and an axis of rotation, wherein rotation of the nozzle about the axis of rotation relative to the reservoir aligns the one or more apertures in the reservoir interface with the one or more apertures in the nozzle cap.

Abstract: A flow control device for a compressible bottle may include a reservoir, the reservoir comprising an ophthalmic formulation disposed therein, the ophthalmic formulation comprising an ophthalmic agent and a preservative; a reservoir interface, disposed at a mouth of the reservoir, the reservoir interface comprising one or more apertures, the one or more apertures in the reservoir interface fluidically connecting an interior of the reservoir and an exterior of the reservoir; a nozzle, the nozzle comprising: an outlet and a nozzle cap, the nozzle cap comprising one or more apertures, the one or more apertures in the nozzle cap fluidically connecting the outlet and a reservoir-facing surface of the nozzle; and an axis of rotation, wherein rotation of the nozzle about the axis of rotation relative to the reservoir aligns the one or more apertures in the reservoir interface with the one or more apertures in the nozzle cap.

Abstract: A flow control device for a compressible bottle may include a reservoir, the reservoir comprising an ophthalmic formulation disposed therein, the ophthalmic formulation comprising an ophthalmic agent and a preservative; a reservoir interface, disposed at a mouth of the reservoir, the reservoir interface comprising one or more apertures, the one or more apertures in the reservoir interface fluidically connecting an interior of the reservoir and an exterior of the reservoir; a nozzle, the nozzle comprising: an outlet and a nozzle cap, the nozzle cap comprising one or more apertures, the one or more apertures in the nozzle cap fluidically connecting the outlet and a reservoir-facing surface of the nozzle; and an axis of rotation, wherein rotation of the nozzle about the axis of rotation relative to the reservoir aligns the one or more apertures in the reservoir interface with the one or more apertures in the nozzle cap.

Abstract: Systems and methods for removing a preservative from a solution, emulsion, or suspension may include an ophthalmic agent, a complexing agent, and a matrix. A method for administering an ophthalmic agent may include: providing a solution, emulsion, or suspension comprising a hydrophobic ophthalmic agent, a preservative, and a complexing agent, wherein the complexing agent is configured to host the hydrophobic ophthalmic agent; and providing a polymeric matrix, wherein the complexing agent is configured to reduce an affinity of the ophthalmic agent for the polymeric matrix and wherein the polymeric matrix is configured to selectively absorb the preservative when the solution, emulsion, or suspension is passed therethrough.

Abstract: The present disclosure relates to nozzles for removing a preservative from a fluid comprising a therapeutic agent to an eye. More particularly, the nozzles disclosed herein may minimize patient exposure to preservative by rapidly and selectively removing a preservative from a solution comprising a therapeutic agent. An example nozzle may comprise a flow diverter which directs a flow path from a fluid inlet to a fluid outlet over a length longer than the distance from the inlet to the outlet. In some cases, the nozzle may comprise a preservative removing agent.

Abstract: The present disclosure relates to nozzles for removing a preservative from a fluid comprising a therapeutic agent to an eye. More particularly, the nozzles disclosed herein may minimize patient exposure to preservative by rapidly and selectively removing a preservative from a solution comprising a therapeutic agent. An example nozzle may comprise a flow diverter which directs a flow path from a fluid inlet to a fluid outlet over a length longer than the distance from the inlet to the outlet. In some cases, the nozzle may comprise a preservative removing agent.

Abstract: A flow control device for a compressible bottle may include a reservoir, the reservoir comprising an ophthalmic formulation disposed therein, the ophthalmic formulation comprising an ophthalmic agent and a preservative; a reservoir interface, disposed at a mouth of the reservoir, the reservoir interface comprising one or more apertures, the one or more apertures in the reservoir interface fluidically connecting an interior of the reservoir and an exterior of the reservoir; a nozzle, the nozzle comprising: an outlet and a nozzle cap, the nozzle cap comprising one or more apertures, the one or more apertures in the nozzle cap fluidically connecting the outlet and a reservoir-facing surface of the nozzle; and an axis of rotation, wherein rotation of the nozzle about the axis of rotation relative to the reservoir aligns the one or more apertures in the reservoir interface with the one or more apertures in the nozzle cap.

Abstract: Systems and methods for removing a preservative from a solution, emulsion, or suspension may include an ophthalmic agent, a complexing agent, and a matrix. A method for administering an ophthalmic agent may include: providing a solution, emulsion, or suspension comprising a hydrophobic ophthalmic agent, a preservative, and a complexing agent, wherein the complexing agent is configured to host the hydrophobic ophthalmic agent; and providing a polymeric matrix, wherein the complexing agent is configured to reduce an affinity of the ophthalmic agent for the polymeric matrix and wherein the polymeric matrix is configured to selectively absorb the preservative when the solution, emulsion, or suspension is passed therethrough.

Abstract: The present disclosure relates to nozzles for removing a preservative from a fluid comprising a therapeutic agent to an eye. More particularly, the nozzles disclosed herein may minimize patient exposure to preservative by rapidly and selectively removing a preservative from a solution comprising a therapeutic agent. An example nozzle may comprise a flow diverter which directs a flow path from a fluid inlet to a fluid outlet over a length longer than the distance from the inlet to the outlet. In some cases, the nozzle may comprise a preservative removing agent.

Abstract: Arterial blood pressure of a subject is determined by detecting the EKG for the subject and selecting a fiducial point on the EKG during a pulse. Apparatus is provided for monitoring blood volume versus time at a selected location on the subject's body such as a fingertip. A time difference between the occurrence of the selected fiducial point on the EKG and a selected change in blood in volume at the selected body location is determined. This time difference depends on the arrival time of the pulse at the distal location in addition to the shape of the blood volume versus time curve. Heart rate is determined from the EKG. The arterial pressure is computed from pulse arrival time, volumetric wave shape and instantaneous heart rate for each pulse. It is preferred that the fiducial point on the EKG be an R-wave. A suitable method for determining change in blood volume utilizes photoplethysmography. Methods are disclosed for determining diastolic pressure, systolic and mean arterial pressure.

Abstract: Arterial blood pressure of a subject is determined by detecting the EKG for the subject and selecting a fiducial point on the EKG during a pulse. Apparatus is provided for monitoring blood volume versus time at a selected location on the subject's body such as a fingertip. A time difference between the occurrence of the selected fiducial point on the EKG and a selected change in blood in volume at the selected body location is determined. This time difference depends on the arrival time of the pulse at the distal location in addition to the shape of the blood volume versus time curve. Heart rate is determined from the EKG. The arterial pressure is computed from pulse arrival time, volumetric wave shape and instantaneous heart rate for each pulse. It is preferred that the fiducial point on the EKG be an R-wave. A suitable method for determining change in blood volume utilizes photoplethysmography. Methods are disclosed for determining diastolic pressure, systolic and mean arterial pressure.